Stelara (Ustekinumab) Market Report 2026

Stelara (Ustekinumab) Market Overview

• The Stelara (Ustekinumab) market growth in the historic period has been driven by limitations of conventional immunosuppressants, rising prevalence of autoimmune diseases • Market expansion is supported by growth in inflammatory bowel disease cases, expansion of biologic reimbursement coverage • Growth Driver: Rising Psoriasis Prevalence Driving Growth In The Stelara (Ustekinumab) Market • Market Trend: Innovation In The Stelara Biosimilar Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Stelara (Ustekinumab) Market?

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune responses. It is widely used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The main types of indication for stelara (ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and others. Plaque psoriasis is a chronic autoimmune condition characterized by the rapid buildup of skin cells, forming scaly, inflamed patches, often on the scalp, elbows, and knees. It can be administered through both subcutaneous injection and intravenous infusion and is distributed through various channels, including hospital pharmacy, retail pharmacy, and online pharmacy. It is used for pediatric, adult, and geriatric.

What Is The Stelara (Ustekinumab) Market Growth Forecast?

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of biologic reimbursement coverage, patient preference for less frequent dosing, biosimilar competition impact, improved biologic delivery devices. Major trends in the forecast period include rising use of targeted biologic therapies, expansion of autoimmune disease indications, shift toward long-term maintenance treatment, growing adoption of subcutaneous biologics, increase in home-based administration.

Global Stelara (Ustekinumab) Market Segmentation

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications 2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End User: Pediatric, Adult, Geriatric

What Is The Driver Of The Stelara (Ustekinumab) Market?

The rise in prevalence of psoriasis patients is expected to propel the growth of the stelara (ustekinumab) market going forward. Psoriasis patients are individuals suffering from a chronic autoimmune disorder that accelerates skin cell turnover, resulting in red, scaly patches. The rise in the prevalence of psoriasis patients can be attributed to several factors, including improved diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) targets and inhibits interleukin-12 and interleukin-23 which helps psoriasis patients by effectively reducing inflammation and plaque formation, leading to improved skin clearance and long-term symptom management, ultimately enhancing their quality of life. For instance, in August 2024, according to a report published by the National Psoriasis Foundation (NPF), a US-based non-profit organization, psoriasis impacts roughly 3% of U.S. adults aged 20 and above, translating to over 7. million individuals. In addition, around 600,000 adults in the country are believed to have psoriasis but remain undiagnosed. Therefore, the rise in prevalence of psoriasis patients is expected to propel the growth of the stelara (ustekinumab) industry.

Key Players In The Global Stelara (Ustekinumab) Market

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Global Stelara (Ustekinumab) Market Trends and Insights

Major companies operating in the stelara (ustekinumab) market are developing innovative products, such as biosimilars to stelara, to provide a cost-effective treatment option for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications developed to replicate the therapeutic effects of Stelara (Ustekinumab), targeting IL-12 and IL-23 to treat autoimmune conditions like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA stands out for its broad indications, offering treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It is also uniquely indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it versatile across age groups. This comprehensive coverage positions IMULDOSA as a valuable option for managing various immune-mediated inflammatory diseases.

What Are Latest Mergers And Acquisitions In The Stelara (Ustekinumab) Market?

In December 2023, Lotus Pharmaceutical, a Taiwan-based pharmaceutical company, partnered with Favorex Pte Ltd. to bring a biosimilar of ustekinumab to South Korean markets.With this partnership, Lotus Pharmaceutical aims to leverage Favorex Pte Ltd.'s expertise and market presence to introduce a biosimilar of ustekinumab to South Korean markets, addressing the demand for cost-effective biologic therapies and expanding its footprint in the region's pharmaceutical sector. Favorex Pte Ltd. is a Singapore-based pharmaceutical company.

Regional Insights

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Stelara (Ustekinumab) Market?

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Stelara (Ustekinumab) Market Report 2026?

The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.